GT Medical Technologies is a Tempe, Arizona medical device company that developed GammaTile, an FDA-cleared bioresorbable radiation therapy implant for operable brain tumors. Founded by brain tumor specialists from the Barrow Neurological Institute, the company places collagen tiles embedded with Cesium-131 seeds directly into the tumor cavity at the time of surgery, delivering immediate, targeted radiation while sparing healthy tissue. Backed by a $100M Series E led by Viking Global Investors, GT Medical has treated more than 2,000 patients and is pursuing randomized trials to establish GammaTile as a standard of care.
Coherence Neuro is a San Francisco medical-device company building closed-loop neurotechnology to treat cancer as a continuously monitored condition rather than a reactive battle. Founded in 2022 by University of Cambridge researchers Ben Woodington and Elise Jenkins, the company decodes the body's electrical signals in real time and delivers adaptive, AI-tuned stimulation through its flagship SOMA system - a wireless implant, wearable, and mobile app working together. Backed by a $10M seed round led by Artesian and Topology Ventures, Coherence aims to begin first-in-human trials in 2026.
Ben Woodington is the co-founder and CEO of Coherence Neuro, a deep-tech company building SOMA-1, a button-sized, MRI-safe brain-computer interface that listens to and electrically modulates brain tumors from the inside. A Cambridge-trained chemist-turned-engineer who once built smart inhalers and minimally invasive spinal-cord interfaces, Woodington pivoted his neurotechnology to oncology after realizing almost no one was applying neural-interface engineering to cancer. He argues electricity should become the fourth pillar of cancer therapy alongside surgery, drugs, and radiation, and raised a $10M seed in late 2025 to take the work toward first human trials.
Autem Therapeutics is a Hanover, New Hampshire bioelectric oncology company developing AutEMsys, a non-invasive, non-toxic device that delivers personalized, low-level, amplitude-modulated electromagnetic frequencies to patients with solid tumors. Founded by medical oncologist Frederico Costa and led by CEO Michael Choukas, the company targets hepatocellular carcinoma (liver cancer) and other hard-to-treat cancers, aiming to make effective cancer care portable, affordable, and accessible worldwide. Its lead program has earned FDA Breakthrough Device designation for advanced HCC.